Results 121 to 130 of about 56,276 (247)

Lymphomatoid Papulosis Following Spesolimab Treatment for Generalised Pustular Psoriasis

Australasian Journal of Dermatology, EarlyView.
Mizuho Namba, Mika Matsumoto, Naoya Saito, Atsuko Kimura, Chihiro Sagara, Daiki Rokunohe, Eijiro Akasaka   +6 more
wiley   +1 more source

Safety of an Intravitreal Bevacizumab Biosimilar (MVASI)

Clinical &Experimental Ophthalmology, EarlyView.
ABSTRACT Background Intravitreal bevacizumab has been used off‐label to treat multiple ocular conditions for almost two decades. Reference bevacizumab, Avastin, was discontinued in Australia in 2021. A bevacizumab biosimilar, MVASI, was approved by the Therapeutic Goods Administration for the treatment of metastatic cancer in 2020.
Hanru Wang, Bobak Bahrami, Sonia Huang, Marzieh Tahmasebi Sarvestani, Sudha Cugati, Stewart Lake, Weng Onn Chan, Devaraj Supramaniam, Matthew Little   +8 more
wiley   +1 more source

Early caplacizumab and obinutuzumab enable successful treatment of relapsing thrombotic thrombocytopenic purpura without therapeutic plasma exchange: a case report. [PDF]

Front Immunol
Schimpf J, Haller P, Zitt E.
europepmc   +1 more source

Haemophilia Prophylaxis in the Age of Innovation: Exploring Opportunities for Personalized Treatment

Haemophilia, EarlyView.
ABSTRACT Introduction Recent advancements in haemophilia treatment have introduced a range of innovative therapies, including activated FVIII mimetics, ultra‐extended half‐life recombinant FVIII, rebalancing agents and gene therapy. These developments have transformed treatment options and expanded prophylaxis strategies.
Yesim Dargaud, Fabienne Volot, Stephanie Desage, Claire Pouplard, Valerie Chamouard, Anne Lienhart   +5 more
wiley   +1 more source

Structural Insights into the ADCC Mechanism and Resistance of Mogamulizumab, a First-in-Class Anti-CCR4 Therapy for Cutaneous T Cell Lymphoma. [PDF]

Int J Mol Sci
Choi SB, Lee HT, Gu N, Jang YJ, Park UB, Jeong TJ, Lee SH, Heo YS.   +7 more
europepmc   +1 more source

TSUBASA Study: Evaluating Association of Physical Activity and Bleeding Events in People With Haemophilia A Without Factor VIII Inhibitors Receiving Emicizumab

Haemophilia, EarlyView.
ABSTRACT Background Emicizumab is approved for routine prophylaxis, but limited data exist investigating the relationship between bleeds and exercise in people with haemophilia A (PwHA) receiving emicizumab. Aim To evaluate the relationship between physical activity and bleeding outcomes in Japanese PwHA receiving emicizumab prophylaxis.
Kagehiro Amano, Teruhisa Fujii, Akihiro Sawada, Azusa Nagao, Chiai Nagae, Masanori Nojima, Nobuaki Suzuki, Mika Kawano, Tomomi Shimura, Yoshimasa Sugao, Naoto Hattori, Keiji Nogami   +11 more
wiley   +1 more source

Passive Immunization in the Prevention and Treatment of Viral Infections. [PDF]

Eur J Immunol
Moirangthem R, Bar-On Y.
europepmc   +1 more source

Pharmacokinetics and safety of eptinezumab in children and adolescents with migraine

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective The primary objective was to characterize the pharmacokinetics (PK) and safety of eptinezumab in children and adolescents with migraine. Background Migraine in children and adolescents is a prevalent and potentially debilitating disease, and few preventive therapies are approved for use in these populations. Eptinezumab, a calcitonin
Andrew D. Hershey, Johan Areberg, Line Pickering Boserup, Annika Lindsten, Monika Rosen   +4 more
wiley   +1 more source

The revolution in pharmacotherapy: from herbs to pills, moulds, antibodies to genetic tools. [PDF]

Eur Heart J Cardiovasc Pharmacother
Lüscher TF.
europepmc   +1 more source

Postmarketing safety of migraine prophylactic monoclonal antibodies: An EudraVigilance database analysis of eptinezumab, fremanezumab, galcanezumab, and erenumab

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objectives/Background This study was undertaken to evaluate the postmarketing safety of monoclonal antibodies (mAbs) targeting the calcitonin gene‐related peptide pathway used for migraine prophylaxis through pharmacovigilance data analysis by examining suspected adverse events reported in Europe.
Victoria Nikitina, Greta Santi Laurini, Nicola Montanaro, Domenico Motola   +3 more
wiley   +1 more source